Cell Source Stock Price, News & Analysis
Company Description
Cell Source, Inc. develops Veto Cell-based immunotherapy technologies for immune tolerance management in transplantation and cell therapy. The company is quoted on the OTCQB under the symbol CLCS and focuses on donor-derived cellular approaches intended to reduce immune rejection in mismatched donor stem cell transplants, organ transplants, and allogeneic immunotherapy products.
The company's central platform is its proprietary Veto Cell technology, an allogeneic cell-therapy approach designed to manage immune response so that transplanted cells can be tolerated by the recipient. Cell Source has described the platform as applicable to stem cell transplantation for malignant and non-malignant hematologic diseases, including settings where a fully matched donor may not be available. The company also links the platform to potential companion-cell use with cellular therapies such as CAR-T and NK-cell approaches, where immune rejection and graft-versus-host disease are major technical barriers.
Veto Cell platform and development focus
Cell Source's development model centers on translating Veto Cells from preclinical and early clinical research into cellular therapy applications. The technology is exclusively licensed from The Weizmann Institute of Science in Israel. Reported applications include mismatched donor bone marrow and stem cell transplantation, treatment approaches for hematologic malignancies and non-malignant blood diseases, and immune-tolerance support for donor-derived CAR-T therapy. The company's recent scientific communications have addressed natural killer cell-mediated rejection, a mechanism that can limit allogeneic cell therapies.
The company has reported both clinical and preclinical work around its platform. Clinical work has involved Veto Cell use in stem cell transplants for malignant and non-malignant hematologic diseases at The University of Texas MD Anderson Cancer Center. Preclinical publications and company updates have also described Veto Cell-based bone marrow transplant protocols in models of sickle cell disease and other transplant settings.
Intellectual property and research orientation
Cell Source has announced U.S. patent activity covering Veto Cell technology, including patents titled Veto Cells Generated from Memory T Cells and Methods of Transplantation and Disease Treatment. These patent disclosures relate to Veto Cells that are intended to support patient acceptance of transplanted cells, address graft rejection and graft-versus-host disease, and act as companion cells with other cellular therapy modalities.
As a development-stage cell therapy company, Cell Source's business is organized around proprietary technology licensing, research collaborations, clinical translation, patent protection, and scientific presentation of immune-tolerance data. Its operating identity is tied to Veto Cell-based immunotherapy rather than commercial sales of approved therapeutics.
Stock Performance
Cell Source (CLCS) stock last traded at $0.8200, up 6.49% from the previous close. Over the past 12 months, the stock has gained 192.9%. At a market capitalization of $52.3M, CLCS is classified as a micro-cap stock with approximately 67.9M shares outstanding.
Latest News
Cell Source has 8 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, management. View all CLCS news →
SEC Filings
Cell Source has filed 2 recent SEC filings, including 1 Form 10-Q, 1 Form 10-K. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CLCS SEC filings →
Financial Highlights
Diluted earnings per share stood at $-0.14.
Upcoming Events
Convertible notes maturity
Cell Source has 1 upcoming scheduled event. The next event, "Convertible notes maturity", is scheduled for June 17, 2026 (in 3 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the CLCS stock price.
Short Interest History
Short interest in Cell Source (CLCS) currently stands at 5.4 thousand shares, up 1.1% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 90.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Cell Source (CLCS) currently stands at 1.4 days, up 22.8% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 40% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 7.9 days.
CLCS Company Profile & Sector Positioning
Cell Source (CLCS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing CLCS often look at related companies in the same sector, including Oncotelic Therapeutics Inc (OTLC), Finch Therapeutics Group, Inc. (FNCH), Biomind Labs Inc (BMNDF), ACCUSTEM SCIENCES INC (ACUT), and Pharmather Holdings Ltd (PHRRF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CLCS's relative position within its industry.